Viatris Inc (VTRS)

Viatris to Present at the Bank of America Securities 2026 Healthcare ConferenceMay 7, 2026 4:30 PM
PR Newswire (US) PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m. ET.Investors and the general public are invited to listen to the live webcast of the event at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About Viatris 
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we strive to deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X.   View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-to-present-at-the-bank-of-america-securities-2026-healthcare-conference-302764839.htmlSOURCE Viatris Inc. Original: Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

Viatris Announces Chief Financial Officer TransitionMay 4, 2026 4:30 PM
PR Newswire (US) Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFOPITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the Company for a new professional opportunity.Viatris has named Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief Financial Officer, effective May 8, 2026, while the Company conducts its search for a permanent successor. Mistras will remain with the Company until May 22, 2026, to facilitate a seamless transition."We thank Doretta for her significant contributions, which have helped prepare the Company to enter a period of sustainable future growth," said Scott A. Smith, CEO, Viatris. "Given Paul's deep knowledge of Viatris and his financial expertise and experience, we are confident he is the right transitional leader to maintain continuity and operational discipline while we focus on positioning the Company for sustained long-term growth."Campbell brings more than two decades of experience in accounting, financial operations and corporate leadership to the position. In his current role as Chief Accounting Officer and Corporate Controller of Viatris, Campbell oversees the Company's global accounting and finance operations. Since joining Viatris' legacy company, Mylan, in 2002, Campbell has played a key role in strengthening financial processes, supporting strategic initiatives and maintaining disciplined financial management across the organization.Prior to his current role, Campbell served as Mylan's Chief Accounting Officer, Senior Vice President and Controller, where he was responsible for the Company's accounting, financial operations and reporting. During his tenure, he has held positions of increasing responsibility across internal audit, business development, corporate development and operations finance, contributing to the Company's growth and transformation. Earlier in his career, Campbell spent nearly a decade at Deloitte & Touche, where he served as a Senior Manager in Audit. Campbell holds a Bachelor of Science in Accounting from Pennsylvania State University.Viatris will release financial results for the first quarter of 2026 on May 7, 2026, and will host a conference call at 8:30 a.m. ET to discuss the results.About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we strive to deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X.Forward-Looking StatementsThis press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that Mistras's significant contributions have helped prepare the company to enter a period of sustainable future growth; and that given Campbell's deep knowledge of the Company, his financial expertise and experience, we are confident he is the right transitional leader to maintain continuity and operational discipline while we focus on positioning the company for sustained long-term growth. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the possibility that the Company may not realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives and priorities; the possibility that the Company may be unable to achieve the intended or expected benefits of its enterprise-wide strategic review and related cost-saving and restructuring activities within the expected timeframe or at all; the possibility that the Company may be unable to achieve intended or expected benefits in connection with divestitures, acquisitions, strategic alliances, collaborations, or other transactions, or restructuring programs, within the expected timeframes or at all; the Company's failure to achieve expected or targeted future financial and operating performance and results; the ability to attract, motivate and retain key personnel; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with U.S. GAAP and related standards or on an adjusted basis; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.  View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-announces-chief-financial-officer-transition-302761799.htmlSOURCE Viatris Inc. Original: Viatris Announces Chief Financial Officer Transition

Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific MeetingMay 1, 2026 6:59 AM
PR Newswire (US)

PITTSBURGH, May 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that six abstracts on its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly patch will be presented at the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting (ACSM) in Washington, D.C., May 1-3, 2026.The presentations will include positive results from the previously announced Phase 3 study (NCT05139121) evaluating the contraceptive efficacy and safety of the Company's investigational low-dose estrogen CHC weekly patch. In addition, presentations will highlight new data on the patch's adhesion profile under normal and under extreme conditions, as well as pharmacokinetic data and data on cycle control.All accepted scientific abstracts are available on the ACOG Annual Meeting website.Full List of Viatris Presentations at 2026 ACOG ACSM:AbstractAbstract DetailsAbstract No. E26Patch Adhesion Performance of a Low-Dose
Estrogen Transdermal Contraceptive System MR-
100A-01Electronic PosterIndustry ePoster Session E (IEP05)Saturday, May 28–9 a.m. EDTAbstract No. E27No impact on adhesion performance and
pharmacokinetics of MR-100A-01 contraceptive
patch under extreme conditionsElectronic PosterIndustry ePoster Session E (IEP05)Saturday, May 28–9 a.m. EDTAbstract No. G19Contraceptive Efficacy of MR-100A-01 in Women of
Childbearing Potential: Results from a Phase 3
StudyElectronic PosterIndustry ePoster Session G (IEP07)Saturday, May 21:30–2:30 p.m. EDTAbstract No. G20MR-100A-01 Weekly Transdermal Contraceptive
System: Safety Insights from a Phase 3 TrialElectronic PosterIndustry ePoster Session G (IEP07)Saturday, May 21:30–2:30 p.m. EDTAbstract No. G21MR-100A-01 Weekly Transdermal Contraceptive
System: Cycle Control Data from a Phase 3 TrialElectronic PosterIndustry ePoster Session G (IEP07)Saturday, May 21:30–2:30 p.m. EDTAbstract No. G22Comparison of the multiple-dose pharmacokinetics
of norelgestromin and ethinyl estradiol following
administration of MR-100A-01, a once-weekly
contraceptive transdermal system, and once daily
administration of oral contraceptive tabletsElectronic PosterIndustry ePoster Session G (IEP07)Saturday, May 21:30–2:30 p.m. EDTIn complement to its scientific program, and to further foster peer-to-peer exchange and support clinicians in the evolving landscape of non-oral contraceptive options, Viatris provided an independent educational grant for the following educational symposium hosted by PRIME®, a nationally recognized continuing medical education platform:Contraceptive Considerations in the Modern Era: Navigating Non-Oral Options and Evolving Clinical ComplexitiesFriday, May 16–7:30 p.m. ETMarriott Marquis Washington, D.C., Salon 5 (Meeting Level 2)More information on the data presentations and symposium can be found on the ACOG ACSM website here, and Viatris can be found at booth #223.About Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch
The investigational treatment is a once-weekly transdermal contraceptive patch being developed for women of childbearing potential with a BMI below 30 kg/m² who are appropriate candidates for combined hormonal contraception (CHC) and who prefer a non-invasive, reversible option with a lower estrogen dose.  The U.S. FDA has accepted for review the New Drug Application (NDA) for the Company's investigational low-dose estrogen CHC weekly patch. The NDA is accepted under the FDA's 505(b)(2) regulatory pathway, and the FDA has assigned a target action date (PDUFA) of July 30, 2026. The NDA is supported by results from a multicenter, open-label, single-arm, Phase 3 study (NCT05139121), which evaluated the safety and contraceptive efficacy of the investigational low-dose estrogen CHC weekly patch, and which demonstrated a favorable efficacy and safety profile and strong patch adhesion performance.The investigational low-dose estrogen CHC weekly patch aims to address an important need for women seeking a reversible birth control method that offers a lower dosage of estrogen in a weekly patch with potential best-in-class adhesion performance. This investigational treatment option builds upon the Company's established capability in transdermal drug delivery and represents a lifecycle advancement of the contraceptive patch, Xulane® (norelgestromin and ethinyl estradiol transdermal system) 150/35 mcg per day.About Viatris 
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we strive to deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X.Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements about the investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly patch; the outcomes of clinical trials; FDA has accepted for review the NDA for the Company's investigational low-dose estrogen CHC weekly patch; the NDA is accepted under the FDA's 505(b)(2) regulatory pathway, and the FDA has assigned a target action date (PDUFA) of July 30, 2026; the NDA is supported by results from a multicenter, open-label, single-arm, Phase 3 study (NCT05139121), which evaluated the safety and contraceptive efficacy of the investigational low-dose estrogen CHC weekly patch and which demonstrated a favorable efficacy and safety profile and strong patch adhesion performance; the investigational low-dose estrogen CHC weekly patch aims to address an important need for women seeking a reversible birth control method that offers a lower dosage of estrogen in a weekly patch with potential best-in-class adhesion performance; this investigational treatment option builds upon the Company's established capability in transdermal drug delivery and represents a lifecycle advancement of the contraceptive patch, Xulane® (norelgestromin and ethinyl estradiol transdermal system) 150/35 mcg per day. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; failure to achieve the intended benefits of our strategic initiatives and priorities; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; failure to achieve expected or targeted future financial and operating performance and results; Viatris' or its partners' ability to develop, manufacture, and commercialize products; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; any significant breach of data security or data privacy or disruptions to our IT systems; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. 





View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-announces-several-data-presentations-on-investigational-low-dose-estrogen-combined-hormonal-contraceptive-weekly-patch-at-the-2026-american-college-of-obstetricians-and-gynecologists-annual-clinical--scientific-meeting-302759662.htmlSOURCE Viatris Inc.

Original: Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting

Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingApril 10, 2026 6:59 AM
PR Newswire (US)

PITTSBURGH, April 10, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026.The presentations will include data across various areas of ophthalmology, including full results from VEGA-3, a Phase 3 study evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia; results from a Phase 1 study of varenicline solution nasal spray in healthy Japanese adults; and a post-hoc analysis of MIRA-2, a Phase 3 study evaluating the optical impact of RYZUMVI® for reversing pharmacologically-induced mydriasis. Additional data will include an encore presentation of LYNX-2, a Phase 3 study evaluating MR-142 (phentolamine ophthalmic solution 0.75%) for visual disturbances in low light conditions in post-refractive surgery patients.All accepted scientific abstracts are available on the ASCRS Annual Meeting website.Full List of Viatris Presentations at ASCRS Annual Meeting 2026:AbstractAbstract DetailsAbstract No. 123806Optical Impact of Reversing Pharmacologically
Induced Mydriasis on Image QualityElectronic Poster (On-Demand)Friday, April 10Room: WEWCCAbstract No. 121513 Changes in Tear Meniscus Height after a Single-
Dose of Varenicline Solution Nasal Spray in Healthy
Japanese Adult VolunteersElectronic Poster (On-Demand)Friday, April 10Room: WEWCCAbstract No. 119626 Phentolamine Ophthalmic Solution Provides
Durable Improvement in Distance Corrected Near
Vision for Presbyopic Patients in a Phase 3 StudyOral PresentationPaper Session: Presbyopia Correction
- Digital & Other  Saturday, April 118–8:05 a.m. ETRoom: WEWCC - Level 2, 209CAbstract No. 119714 Phase 3 Randomized Controlled Study of
Phentolamine Ophthalmic Solution in Post-
Refractive Surgery Patients with Impaired
Mesopic VisionOral PresentationPaper Session: Refractive
Complications, Digital, & Other  Saturday, April 118:20–8:25 a.m. ETRoom: WEWCC - Level 2, 209ATo complement its scientific program, and to further foster peer-to-peer exchange and support clinicians in the evolving management of presbyopia, Viatris provided an independent educational grant for the following educational symposium hosted by PRIME®, a nationally recognized continuing medical education platform:Presbyopia Re-Envisioned: A New Era of Pharmacological Vision CorrectionSaturday, April 116–7:30 p.m. ETThe Westin DC Downtown, River Birch BallroomMore information on the data presentations and symposium can be found on the ASCRS website here, and Viatris can be found at booth #233.All educational content of the ASCRS Annual Meeting is planned by its Program Committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services.Opus Genetics and Viatris (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants exclusive rights to Viatris to commercialize phentolamine ophthalmic solution 0.75% in the U.S.About Presbyopia
Presbyopia is the gradual loss of near focusing ability due to aging, that typically becomes noticeable in the early to mid-40s. It is a nearly universal condition that, when uncorrected, contributes significantly to vision-related disability. Presbyopia leads to symptoms like eye strain and blurred near vision, impacting daily tasks and productivity. It affects nearly 128 million people in the United States—about 90% of adults over 45. By age 50, most Americans require some form of near-vision correction, such as reading glasses or multifocal lenses. Globally, an estimated 1.8 billion people were presbyopic in 2015, projected to rise to 2.1 billion by 2030.RYZUMVI® IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Uveitis: RYZUMVI is not recommended to be used in patients with active ocular inflammation (e.g., iritis).
Potential for Eye Injury or Contamination: To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
Use with Contact Lenses: Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.
Adverse Reactions
The most common adverse reactions that have been reported are instillation site discomfort (16%), conjunctival hyperemia (12%), and dysgeusia (6%).Please see Full Prescribing InformationAbout Mesopic Vision
Mesopic vision is defined as vision in dim light (interface of bright light and night vision) conditions that leverages both rod and cone photoreceptors. Decreased low contrast visual acuity under mesopic conditions occurs when the pupil dilates in low-light conditions allowing peripheral unfocused rays of light to enter the eye. The total diagnosed prevalence of Night Vision Disturbance (NVD) across the 7 Major Markets (United States, United Kingdom, Germany, France, Italy, Spain, and Japan) was estimated to be nearly 55 million in 2023, with the U.S. representing approximately 45% of cases. The condition is particularly common in patients with increased ocular aberrations and ocular scatter from keratorefractive surgery (including Laser-Assisted In Situ Keratomileusis (LASIK), Photorefractive Keratectomy (PRK), Small-Incision Lenticule Extraction (SMILE), and Radial Keratotomy (RK)). It is estimated that approximately 800,000 refractive surgeries are performed in the U.S. each year, with 25% of patients suffering from visual aberrations (e.g., glare, halos, starburst) at 1-month. There are currently no FDA-approved treatments.About Viatris 
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we deliver solutions that are effective at scale and built to endure. We're purpose-built to make an impact with a dynamic portfolio that spans generics, established brands and innovative medicines that address areas of significant unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, China, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X.Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements about presentations, study results, and licensing agreements. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; failure to achieve the intended benefits of our strategic initiatives and priorities; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; failure to achieve expected or targeted future financial and operating performance and results; Viatris' or its partners' ability to develop, manufacture, and commercialize products; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; any significant breach of data security or data privacy or disruptions to our IT systems; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.





View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-announces-multiple-data-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-annual-meeting-302738923.htmlSOURCE Viatris Inc.

Original: Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting

Viatris (VTRS) reported strong Q4 results with revenues of $14.3 billion and adjusted EBITDA of $4.2 billion. UBS raised its price target to $20 amid improved cost-saving initiatives and growth outlook.

Viatris tops forecasts as earnings and revenue beat expectationsFebruary 26, 2026 9:45 AM
IH Market News
Viatris Inc (NASDAQ:VTRS) reported fourth-quarter results that came in ahead of Wall Street forecasts, lifting its shares modestly in premarket trading.The pharmaceutical group posted adjusted earnings per share of $0.57, exceeding analyst expectations of $0.54. Revenue reached $3.7 billion, topping the consensus estimate of $3.53 billion and marking a 5% increase compared with the same period last year.Shares rose 1.4% ahead of the market open following the announcement.On a reported basis, revenue grew 5% year over year, while operational growth — adjusted for divestitures — came in at 2%.Sales of branded products performed strongly in Greater China and Emerging Markets, helping offset ongoing pressure in the generics business, where competition in North America and government pricing regulations in Japan weighed on performance.For the full year, Viatris generated operating cash flow of $2.3 billion and returned more than $1 billion to shareholders during 2025.“2025 was a year of strong execution across our global business, and we enter 2026 from a position of strength,” said Scott A. Smith, CEO of Viatris. “By realigning resources and prioritizing investments in the areas we believe will drive the greatest impact, we are positioning Viatris to deliver sustained revenue and earnings growth beginning in 2026.”Looking ahead, the company forecast fiscal 2026 adjusted earnings per share of $2.33 to $2.47, with a midpoint of $2.40 slightly above analyst expectations of $2.39. Revenue is projected between $14.45 billion and $14.95 billion, with the midpoint of $14.7 billion exceeding the $14.37 billion consensus estimate.Viatris also completed an enterprise-wide strategic review aimed at improving efficiency, targeting $650 million in total cost savings while reinvesting up to $250 million over the next three years.As part of its restructuring program, the company expects to reduce its global workforce by up to 10%. Separately, a fire at its manufacturing facility in Nashik, India temporarily halted production in February, with operations anticipated to resume in April 2026.Viatris stock price

Original: Viatris tops forecasts as earnings and revenue beat expectations

Viatris Maintains Dividend Policy for 2026 and Announces Quarterly DividendFebruary 26, 2026 6:55 AM
PR Newswire (US)

PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2026, to shareholders of record as of the close of business on March 9, 2026. This marks the sixth consecutive year the Company has paid a dividend.                 About Viatris 
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X.Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that Viatris' Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock, payable on March 18, 2026, to shareholders of record as of the close of business on March 9, 2026. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; longer review, response and approval times as a result of evolving regulatory priorities and reductions in personnel at health agencies; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.





View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-maintains-dividend-policy-for-2026-and-announces-quarterly-dividend-302697710.htmlSOURCE Viatris Inc.

Original: Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026February 3, 2026 4:34 PM
PR Newswire (US)

PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.In addition, Viatris will host an Investor Event on March 19, 2026, in New York City. More details regarding the event will be provided during the Company's February investor call.Analysts and institutional investors will be invited to pre-register for the event and attend through an invite that will be distributed separately. Interested parties will also be able to access a live webcast of the event at investor.viatris.com. A replay of the webcast also will be available on the website.About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X. 





View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026-and-host-investor-event-on-march-19-2026-302678203.htmlSOURCE Viatris Inc.

Original: Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

This is a horrible stock to own.

~bought some 3/15 $16 calls @.04 ahead of earnings tomorrow

VTRS new 52=week high

Pfizer Inc came out with Lyrica
Pregabalin (Lyrica) is a medication that treats nerve pain by calming overactive nerves.
It can also treat epilepsy.
Pfizer transferred Lyrica to Viastris Inc
Here is promising Drug Company for Epilepsy
$RSPI .0013
RespireRx Pharmaceuticals Ticker: RSPI
Is working on Revolutionary New Hope:
KRM-II-81 Drug-Resistant Epilepsy Patients

Link found on National Library of Medicine
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders

https://pubmed.ncbi.nlm.nih.gov/35041859/

https://www.neurexplain.com/2024/01/17/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients/

National Institutes of Health
A clinical case of a 19-year-old male patient with pharmacoresistant seizures occurring following parieto-occipital tumor-resection at age 6 ...
KRM–II–81 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784158/

The value of human epileptic tissue in the characterization and development of novel antiepileptic drugs: The example of CERC-611 and KRM-II-81
https://www.sciencedirect.com/science/article/abs/pii/S000689931930410X

VTRS reports 4Q22 results—issues 2023 guidance:

https://www.prnewswire.com/news-releases/viatris-reports-strong-fourth-quarter-and-full-year-2022-financial-results-and-provides-2023-financial-guidance-301756171.html

Nothing that's been publicly disclosed.

VTRS names new CEO:

https://www.prnewswire.com/news-releases/viatris-announces-appointment-of-scott-a-smith-as-ceo-effective-april-1-2023-301756490.html

Scott Smith was already a VTRS director and was formerly the COO of Celgene.

VTRS anything going on? Related to RVNC? eom

VTRS anything going on? Related to RVNC? eom

VIATRIS - FDA APPROVES GENERIC FORM OF SYMBICORT

CLICK FOR FDA LINK


FDA Approves First Generic of Symbicort to Treat Asthma and COPD

Agency Supports Development of Complex Generic Drug-Device Combination Product to Improve Competition and Access to More Affordable Medicines


For Immediate Release:
March 15, 2022

Today, the U.S. Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions: asthma in patients six years of age and older; and the maintenance treatment of airflow obstruction and reducing exacerbations for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. This complex generic drug-device combination product, which is a metered-dose inhaler, should not be used to treat acute asthma attacks.

“Today’s approval of the first generic for one of the most commonly prescribed complex drug-device combination products to treat asthma and COPD is another step forward in our commitment to bring generic copies of complex drugs to the market, which can improve quality of life and help reduce the cost of treatment,” said Sally Choe, Ph.D., director of the Office of Generic Drugs in the FDA Center for Drug Evaluation and Research. “This reflects the FDA’s continued efforts to increase competition and access to quality, safe, effective and affordable medicines for patients and consumers.”

Asthma impacts 25 million people, more than five million of whom are children, while COPD afflicts more than 16 million, according to the National Heart, Lung, and Blood Institute. Asthma is a chronic, long-term condition that affects the airways in the lungs, which can be worsened by physical activity and most often starts during childhood. It can cause wheezing (a whistling sound when breathing), shortness of breath, and coughing. COPD, which includes emphysema and chronic bronchitis, is a long-term, chronic disease that causes airflow blockage and makes it difficult to breathe.

This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing). Two inhalations, two times a day (usually morning and night, about 12 hours apart), treat both diseases by preventing symptoms, such as wheezing for those with asthma, and by helping with better breathing, for those with COPD. The inhaler is approved for two strengths (160/4.5 mcg/actuation and 80/4.5 mcg/actuation).

The most common side effects associated with budesonide and formoterol fumarate dihydrate oral inhalation aerosol for those with asthma are nasopharyngitis (swelling of nasal passages and back of throat), headache, upper respiratory tract infection, pharyngolaryngeal (nose and mouth) pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis (thrush). For those with COPD, the most common side effects are nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection.

The FDA regularly takes steps to help guide industry through the development process for generic drug products, including combination products, such as MDIs, that consist of a drug and a device. To further facilitate generic drug development, and to assist the generic pharmaceutical industry in this process, the FDA publishes product-specific guidances (PSGs) describing the agency’s current thinking and expectations on how to develop generic drug products that are therapeutically equivalent to their brand name counterparts. In June 2015, FDA published a PSG for budesonide and formoterol fumarate dihydrate inhalation aerosol.

The FDA requires sponsors to submit appropriate data and information to demonstrate that complex generic drug-device combination products meet the agency’s rigorous approval standards. These standards ensure that generic drug products are as safe and effective as their brand name equivalents and meet the same high quality standards.

Complex products are medical products where uncertainty concerning the approval pathway or possible alternative approaches to product development can benefit from early scientific engagement, such as products with complex active ingredients and drug-device combination products.

Since drug-device combination products can be more challenging to develop, fewer exist, resulting in less market competition. Addressing the challenges related to complex generics, and promoting more generic competition to these medicines, is a key part of the FDA’s Drug Competition Action Plan, and the agency’s efforts to promote patient access and more affordable medicines.

The FDA granted approval of this generic budesonide and formoterol fumarate dihydrate inhalation aerosol to Mylan Pharmaceuticals, Inc.



The TE

VTRS sells JV stake in Humira/Enbrel/Eylea-biosimilars portfolio_to Biocon for $3B plus contingencies…

4Q21 results:
https://investor.viatris.com/news-releases/news-release-details/viatris-reports-strong-fourth-quarter-and-full-year-2021

CC slides:
https://investor.viatris.com/static-files/6a055dc2-4cd2-4d6c-91c9-c426ec1dcbce

Note: VTRS is retaining its participation in the Botox-biosimilar program with RVNC.

FDA approves VTRS’ generic Restasis—the first US generic for that brand:

https://www.prnewswire.com/news-releases/fda-approves-first-generic-of-restasis-301474142.html

sees u r right, good sign

This one should be trading over $15.00, some very corrupted MM's and the same manipulation coming from hedge funds going on, to keep it down, going into their earnings call and company big updates, there could be a run up that knocks all of the corrupted MM and henge fund trash onto their naked shorting butts in Jan going into Feb.

Fed.Cir. holds certain SNY patents, involving Lantus insulin pen, invalid in infringement suit against VTRS, per Bloomberg news.

Shorts are getting closer and closer to getting blown out and their butts handed to them, they better stop stacking on the offer the Jan 21 $15.00 calls, the dumbasses are going to end up having to buy them back higher.

Viatris (VTRS) “could combine biosimilars with Biocon and keep the optionality on IPO - doesn’t have to decide now.” the analyst wrote, adding $4 per share estimated for biosimilar business to indicate over $20 per share value for the company.

He probably would do that if you subscribe to his bashbag service, and even use whip cream for his own enjoyment.

Clay eat my sack

Viatris Inc. Announces Inaugural Quarterly Dividend

Board of Directors declared a quarterly dividend of eleven cents ($0.11) for each issued and outstanding share of the company's common stock. The dividend is payable on June 26, 2021 to stockholders of record at the close of business on May 24, 2021.

* * $VTRS Video Chart 05-10-2021 * *

Link to Video - click here to watch the technical chart video

hm, I bought in at 43 or so, don't know whats the real prob with it

$13 seems like a great buy-in price for a long hold. Dividend coming and should only be up from here.

Viatris CEO Heather Bresch is the daughter of West Virginia Senator Joe Manchin. More powerful connections for Doc?

Excellent VTRS swing so far...

Nice rebound as expected! So long as we don't get a major market correction (which we could any day), I expect this will be a great long hold.

Yep, I'm having a hard time keeping up w/ the whipsaw call/put action.

Sorry, meant 2Million (not billion)

Looks like 2B shares were added today, driving price down a bit. Once those are all bought up, price will rise back up. Good day to buy IMO.

It's looking good the past few days, even with the delay:

https://www.biocon.com/biocon-biologics-statement-on-the-status-of-bevacizumab-fda-action-date-in-dec-2020/

VTRS.... the only good thing
that came out of owning PFE stock ;)

Run Forrest, Run!

Opened a long straddle today. Go VTRS, move!

$VTRS moving higher, chart gaining momo as it moves towards 20

Old news, chart indicates heading higher towards 20-25 within 3-4 months

Vitaris, Pfizer announced that it would merge its off-patent branded and generic established medicines business, known as Upjohn, with Mylan. The transaction created a new company, Viatris, using a reverse Morris trust structure.[80][third-party source needed] The new business will trade on the NASDAQ stock exchange under the ticker NASDAQ: VTRS.[80] Pfizer shareholders would own 57% of the new combined business. The Board of Viatris will be composed of Robert J. Coury as Executive Chairman (currently Executive Chairman of Mylan), Michael Goettler as CEO (currently Global President of Upjohn), eight people chosen by Mylan and three chosen by Pfizer. In December 2019, Pfizer chose former CEO and Chairman, Ian Read and current Director of Pfizer, James Kilts. In February 2020 Pfizer announced W. Don Cornwell and their final Board selection with Mylan selecting JoEllen Lyons Dillon, Neil Dimick, Melina Higgins, Harry A. Korman, Rajiv Malik, Richard A. Mark, Mark W. Parrish and Pauline van der Meer Mohr as their Board nominees – all current directors of Mylan.[80]

In October 2020, the US Federal Trade Commission approved the combination.[81]

Viatris (VTRS)

$VTSR moving in right direction..

Chart gaining strength. Next stop 21.00ps

$VTRS gaining notice by the hedge funds! Looking vg here

Looking to move much higher!

I’m not going anywhere and will hold. It will take a few months for The Street to start pounding the table. 12 month target 25-30

Viatris Inc. (VTRS) investors to reap big returns again




https://marketingsentinel.com/2020/12/01/viatris-inc-vtrs-investors-to-reap-big-returns-again/